FiercePharma18h
Launch metrics of Madrigal's MASH drug Rezdiffra track 'exceptionally well,' CEO says
Three months ago, in its third-quarter report, Madrigal pointed out that it achieved a key goal early by gaining 80% coverage ...
Madrigal price target raised to $405 from $400 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $405 from $400 and keeps a Buy rating on the shares ...
Madrigal Pharmaceuticals price target raised to $469 from $378 at Citi
Citi raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $469 from $378 and keeps a Buy rating on the shares post the Q4 ...
Nvidia, Constellation Brands downgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...
Hosted on MSN20h
Madrigal Pharmaceuticals Reports Strong 2024 Growth Fueled by Rezdiffra Launch
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced its financial results for 2024, marking a ...
The American Journal of Managed Care20h
Resmetirom Reduces Liver Stiffness in MASH-Compensated Cirrhosis
At 2 years, participants in the compensated MASH cirrhosis treatment arm of the MAESTRO-NAFLD-1 trial experienced a ...